SCHEMBL8638802

SCHEMBL8638802

CC(=O)c1ccccc1OCC(O)CN1CCN(c2ccccc2)CC1

nearest known ligand 0.85

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 17/20 0.85
USP2 O75604 1/20 0.74
ALDH1A1 P00352 1/20 0.74
LMNA P02545 1/20 0.74
TP53 P04637 1/20 0.74
GAA P10253 1/20 0.74
THRB P10828 1/20 0.74
ALOX15 P16050 1/20 0.74
TSHR P16473 1/20 0.74
HTT P42858 1/20 0.74
KMT2A Q03164 1/20 0.74
HTR7 P34969 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8654803 0.88 ABCB1 (0.72) ABCB1TP53GAATHRBKMT2A
SCHEMBL7289913 0.83 ABCB1 (0.78) ABCB1USP2ALDH1A1LMNATP53
SCHEMBL8610306 0.81 MAPT (0.70) ABCB1USP2ALDH1A1LMNATP53
SCHEMBL10508713 0.80 MAPT (0.62) ABCB1GAAKMT2AHTR7
SCHEMBL3641483 0.80 MAPT (0.62) ABCB1TP53GAATHRBKMT2A
SCHEMBL7713577 0.79 MAPT (1.00) USP2ALDH1A1LMNATP53GAA
SCHEMBL8613867 0.79 MAPT (0.82) ALDH1A1LMNAGAAALOX15TSHR
SCHEMBL7862476 0.78 ABCB1 (0.65) ABCB1USP2ALDH1A1LMNATP53
SCHEMBL9815965 0.77 HTR7 (0.76) ABCB1ALDH1A1LMNAALOX15KMT2A
SCHEMBL9015935 0.77 ALDH1A1 (0.74) ALDH1A1LMNAGAAALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0833639-A1 PHENOXY PIPERAZINE DERIVATIVES FOR TREATING DISORDERS OF THE DOPAMINE SYSTEM F. HOFFMANN-LA ROCHE AG (CH) 1998-04-08 EP disclosed
US-5614526-A IN TREATING DISORDERS OF THE DOPAMINE SYSTEM HOFFMANN-LA ROCHE INC. (US) 1997-03-25 US disclosed
WO-1996041630-A1 PHENOXY PIPERAZINE DERIVATIVES FOR TREATING DISORDERS OF THE DOPAMINE SYSTEM F. HOFFMANN-LA ROCHE AG (CH) 1996-12-27 WO disclosed